Our Services
Medical Information
Helpful Resources
Published on: 5/21/2026
Stopping Xolair often leads to recurrent hives because the drug’s effect wanes, allowing free IgE to rebound, immune memory to ramp up IgE production, and primed mast cells to release histamine again. Remission duration varies widely among patients based on factors such as baseline IgE, disease history, and comorbid conditions.
There are several factors to consider for minimizing relapse risk and guiding next steps in your healthcare journey, so see below for more details on predictors of relapse, management strategies, and when to seek medical advice.
Chronic spontaneous urticaria (CSU), commonly known as chronic hives, affects up to 1% of the population. For many, Xolair (omalizumab) brings dramatic relief by targeting immunoglobulin E (IgE) and calming the immune response. But a key question often arises: stopping xolair do hives return? Understanding why urticaria may flare again after discontinuation involves exploring the science of remission, underlying immune processes, and clinical experience.
Xolair is a monoclonal antibody that binds to free IgE in the bloodstream. By reducing IgE levels, Xolair:
Patients often see marked improvement within weeks. However, Xolair does not cure the underlying tendency toward urticaria—it controls it as long as the drug remains in the body.
In immunology, "remission" means the absence or marked reduction of symptoms for an extended period. For CSU:
Studies suggest remission rates vary widely—anywhere from 10% to 40% of patients have sustained remission after stopping Xolair. This variability depends on factors like disease duration, age, baseline IgE levels, and comorbid conditions.
When you ask "stopping xolair do hives return," the answer lies in immunological memory and the persistence of the root cause:
Underlying Disease Activity Persists
Rebound of Free IgE Levels
Immune System Memory
Variable Remission Duration
Several key trials have shed light on relapse patterns:
ASTERIA I & II
Patients with CSU treated with omalizumab 300 mg saw symptom improvement in 75–90%. However, when treatment stopped, about half experienced a return of hives within 8–16 weeks.
GLACIAL Trial
Focused on antihistamine-refractory CSU, it confirmed sustained benefit during treatment and a gradual loss of control after stopping Xolair, often coinciding with rising IgE.
Real-World Registries
Observational data show relapse rates up to 60% within 3–6 months. Longer treatment durations (12–24 months) may slightly prolong remission but don't guarantee prevention of relapse.
Certain factors increase the likelihood that hives will return after stopping Xolair:
Understanding your individual risk can help guide decisions about treatment duration and monitoring.
If hives do return after stopping Xolair, consider these steps:
Reassess Antihistamine Therapy
Consider Restarting Xolair
Emerging Treatments
Lifestyle and Trigger Management
To manage the risk of relapse:
Hives can dramatically impact daily life, but certain signs demand urgent attention:
If you're experiencing new or worsening symptoms and need help understanding what they might mean, try using this Medically approved LLM Symptom Checker Chat Bot for instant, personalized guidance before your doctor's appointment.
And always speak to a doctor about anything that could be life threatening or serious.
By understanding the remission science behind stopping Xolair, you and your doctor can craft a personalized plan to minimize relapse risk and maintain a better quality of life.
(References)
* Maurer M, et al. Persistence of response and relapse rates after discontinuation of omalizumab in chronic spontaneous urticaria: a systematic review. J Allergy Clin Immunol Pract. 2020 Jul;8(7):2263-2270.e1. doi: 10.1016/j.jaip.2020.03.041. Epub 2020 Apr 8. PMID: 32278912.
* Kim JH, et al. Relapse of chronic spontaneous urticaria after discontinuation of omalizumab: A real-world experience. J Am Acad Dermatol. 2021 Jan;84(1):213-214. doi: 10.1016/j.jaad.2020.07.031. Epub 2020 Jul 14. PMID: 32663673.
* Kolkhir P, et al. Recurrence of chronic spontaneous urticaria after discontinuation of omalizumab: predictors and risk factors. Allergy. 2022 Feb;77(2):657-669. doi: 10.1111/all.15011. Epub 2021 Sep 9. PMID: 34509176.
* Song Y, et al. Factors associated with recurrence of chronic spontaneous urticaria after omalizumab discontinuation: A real-world multicenter study. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e178-e180. doi: 10.1111/jdv.18567. Epub 2022 Oct 26. PMID: 36281691.
* Maurer M, et al. Omalizumab treatment of chronic spontaneous urticaria and the prediction of treatment response, remission, and relapse. Expert Rev Clin Immunol. 2023 Apr;19(4):369-380. doi: 10.1080/1744666X.2023.2185458. Epub 2023 Mar 14. PMID: 36877717.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.